A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC

F Cortiula; J Naidoo

doi:10.1016/j.lungcan.2023.107256

A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC

F Cortiula^*, J Naidoo

^*Corresponding author for this work

GROW - Innovative Cancer Diagnostics & Therapy

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Article number	107256
Number of pages	3
Journal	Lung Cancer
Volume	181
Issue number	1
DOIs	https://doi.org/10.1016/j.lungcan.2023.107256
Publication status	Published - Jul 2023

Keywords

Humans
Lung Neoplasms
Neoadjuvant Therapy
Carcinoma, Non-Small-Cell Lung
Aniline Compounds
ErbB Receptors/genetics
Mutation
Protein Kinase Inhibitors

Access to Document

10.1016/j.lungcan.2023.107256

Cite this

@article{6ac16bb43ff94262b3281b2e2f7532b5,

title = "A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC",

keywords = "Humans, Lung Neoplasms, Neoadjuvant Therapy, Carcinoma, Non-Small-Cell Lung, Aniline Compounds, ErbB Receptors/genetics, Mutation, Protein Kinase Inhibitors",

author = "F Cortiula and J Naidoo",

year = "2023",

month = jul,

doi = "10.1016/j.lungcan.2023.107256",

language = "English",

volume = "181",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - A brave NEO world

T2 - Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC

AU - Cortiula, F

AU - Naidoo, J

PY - 2023/7

Y1 - 2023/7

KW - Humans

KW - Lung Neoplasms

KW - Neoadjuvant Therapy

KW - Carcinoma, Non-Small-Cell Lung

KW - Aniline Compounds

KW - ErbB Receptors/genetics

KW - Mutation

KW - Protein Kinase Inhibitors

U2 - 10.1016/j.lungcan.2023.107256

DO - 10.1016/j.lungcan.2023.107256

M3 - Editorial

C2 - 37267713

SN - 0169-5002

VL - 181

JO - Lung Cancer

JF - Lung Cancer

IS - 1

M1 - 107256

ER -